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Introduction {#sec005}
============

According to the WHO, 19% of the 10.6 million deaths occurring each year worldwide in children younger than 5 years of age are attributable to pneumonia \[[@pone.0199989.ref001]\]. *Streptococcus pneumoniae* (Sp) is the main cause of community acquired bacterial pneumonia representing 30--50% of cases \[[@pone.0199989.ref002]\]. However, quantifying the burden of pneumococcal pneumonia is difficult since Sp is not commonly isolated from blood cultures or pleural fluid, although currently available PCR techniques have improved detection \[[@pone.0199989.ref003]\]. The prevalence of Sp nasopharyngeal carriage varies from 27% to 85% in developed and developing countries respectively and severe pneumonia accounts for 18% of all cases with high mortality rates in this age group \[[@pone.0199989.ref004], [@pone.0199989.ref005]\].

In recent decades, many population-based and hospital-based epidemiological surveillance studies were carried out in Latin America and the rest of the world to estimate the burden of pneumonia in children based on radiological \[Consolidated Pneumonia (CP)\] and/or microbiological \[Pneumococcal Pneumonia (PP)\] definitions \[[@pone.0199989.ref006]--[@pone.0199989.ref009]\].

Prevalence of Sp serotypes and bacterial resistance were assessed in order to estimate potential benefits of the new pneumococcal conjugate vaccines (PCVs). At the same time, several clinical trials were carried out showing the efficacy and safety of these vaccines against CP and PP in children \[[@pone.0199989.ref010]--[@pone.0199989.ref014]\].

Based on this evidence and on a local cost-effectiveness analysis, the Argentine Ministry of Health introduced the 13-valent pneumococcal conjugate vaccine (PCV13) into the National Immunization Program in January 2012 using a 2, 4 and 12 months schedule and a two-dose catch-up for all children under 2 years of age born between 2010 and 2011 \[[@pone.0199989.ref015]\]. Before this date, PCVs had not been included in the National Program. Immunization coverage rates for the 1^st^ and 3^rd^ vaccine doses were 69% and 41% in 2012, 98% and 86% in 2013, 99% and 89% in 2014 and, 92% and 82% in 2015 respectively \[[@pone.0199989.ref016]\].

The aims of this study were to evaluate the impact of PCV13 in reducing the burden of CP and PP, and to describe epidemiological-clinical patterns of PP observed during the three years following vaccine introduction.

Methods {#sec006}
=======

Study design and population {#sec007}
---------------------------

This was an analytical, prospective, active surveillance and retrospective study of pneumonia hospitalizations in children conducted at 10 sentinel pediatric hospitals in Argentina: the Ricardo Gutierrez, Pedro de Elizalde and San Justo Children's Hospitals in Buenos Aires, Niño Jesus Children´s Hospital in Tucumán, Victor Vilela Children's Hospital in Rosario, Humberto Notti Pediatric Hospital in Mendoza, Orlando Alassia Children's Hospital in Santa Fe, Juan Pablo II Pediatric Hospital in Corrientes, Héctor Quintana Children's Hospital in Jujuy and Eva Perón Children's Hospital in Catamarca.

All sentinel sites had qualified healthcare staff the infrastructure to diagnose (imaging procedures in line with WHO criteria and microbiological analyses) and treat children hospitalized for pneumonia, as well as the logistics for carrying out surveillance activities.

For the prospective study (2012--2014), study investigators were trained to collect data in a standardized manner using: surveillance records, laboratory and sample submission records, and a case report form containing medical history, nursing reports, and laboratory and microbiology data. Hospital and laboratory databases were used for the retrospective study (2007--2011).

Inclusion criteria {#sec008}
------------------

All children ≤15 years of age with CP hospitalized in one of the sentinel hospitals between January 1^st^ 2007 and December 31^th^ 2014 were included in hospital discharge rate calculations.

Hospitalized children with PP during the three years following vaccine introduction were included in the epidemiological-clinical analysis.

Data collection {#sec009}
---------------

A case report form was completed for each patient with PP containing the following information: participating center, patient's identification code, admission date, demographic data, age, sex, PCV13 vaccination history, underlying illnesses (such as chronic respiratory diseases, cardiovascular diseases, kidney disorders, metabolic disorders, endocrine disorders -including diabetes-, neurological and neurodevelopmental conditions, genetic disorders, blood disorders, and immunosuppression--including oncohematologic disease, immunosuppression therapy, HIV-), nutritional condition, recent acute respiratory infection (common cold, sore throat, flu-like symptoms, otitis or bronchiolitis in 4 weeks before hospitalization), hospitalizations in the last year, previous antibiotic therapy in the last 3 months, bacteriologic cultures and antibiotic susceptibility, isolation sites, clinical evolution, complications, antibiotic therapy and condition at discharge.

Definitions {#sec010}
-----------

Consolidated Pneumonia was defined as any case with chest X-ray showing dense, white image, cotton wool-like appearance (alveolar infiltrate), involving one or more pulmonary segments, lobes or the whole lung, frequently presenting air bronchogram and sometimes associated with pleural effusion \[[@pone.0199989.ref017]\].

Pneumococcal Pneumonia was defined as a case of pneumonia in which Sp was isolated from blood or pleural fluid.

Microbiological studies {#sec011}
-----------------------

Blood and pleural fluid samples were submitted to microbiological testing. Pleural fluid samples were available only for patients who underwent therapeutic thoracocentesis.

*S*. *pneumoniae* isolates were sent to the Clinical Bacteriology Service at the National Institute for Infectious Diseases, National Administration of Health Laboratories and Institutes (INEI-ANLIS) "Dr. Carlos G. Malbran", for confirmation and capsular serotyping by Quellung reaction. Antimicrobial susceptibility testing was performed by agar diffusion method, and Minimum Inhibitory Concentrations (MIC) were determined using agar microdilution method or *E-test®*, according to Clinical Laboratory Standards Institute (CLSI) standards \[[@pone.0199989.ref018]\].

Statistical study {#sec012}
-----------------

Categorical variables were described as percentages and analyzed through Chi-Squared test with Yates' correction or Fisher exact test if expected values were \<5.

We estimated the number of CP and PP hospitalizations per 10,000 hospital discharges for children ≤ 15 years of age, hospitalized for any cause, per year. Changes in CP and PP rates between the pre-vaccination period 2007--2011 (preVp), the year when PCV13 was introduced (intervention year, 2012) and the post-vaccination period 2013--2014 (postVp) were assessed using the Preventive Fraction in exposed (PFe) formula PFe% = \[(Rate preVp--Rate postVp)/ Rate preVp\] x 100, with 95% confidence intervals (CIs).

Statistical analysis was performed using Epi Info TM 7 (CDC, Atlanta) and the Open Epi (Open Source Epidemiologic Statistics for Public Health, Version. [www.OpenEpi.com](http://www.OpenEpi.com), updated on: 2013/04/06). Two-tailed *P* values \<0.05 were considered statistically significant.

Ethics {#sec013}
------

Data were stored in a restricted database, and personal information was recorded under alphanumeric coding, to keep investigators blind to patients' identification.

The study was approved by the Research Ethics Committee at each participating hospital.

Results {#sec014}
=======

Impact of PCV13 vaccination on burden of CP and PP {#sec015}
--------------------------------------------------

### Discharge rates for CP and PP {#sec016}

Analysis of discharge rates by age group showed statistically significant reduction in CP in children \<5 years \[% reduction (95%CI)\]: 10.2% (6.3--14.0) in the intervention year (2012) and 24.8% (21.2--28.2) in the postVp, mainly in the age group from 12 to 23 months during both periods. In children \>5 years, a 13.8% (5.2--21.6) reduction was observed in the postVp ([Table 1](#pone.0199989.t001){ref-type="table"} and [Fig 1](#pone.0199989.g001){ref-type="fig"}).

![Discharge rate of consolidated pneumonia by age group during 2007--2014.](pone.0199989.g001){#pone.0199989.g001}

10.1371/journal.pone.0199989.t001

###### Consolidated pneumonia discharge rates by age.

PCV13 vaccination impact.

![](pone.0199989.t001){#pone.0199989.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age Group       Pre-Vaccination Period: 2007--2011\   Intervention Period: 2012   Post-Vaccination Period: 2013--14\                                                                       
                  (Annual average)                                                  (Annual Average)                                                                                         
  --------------- ------------------------------------- --------------------------- ------------------------------------ ------- ------ -------- ------------------- ------- ------ -------- -------------------
  0--11 months    23029                                 1873                        813.32                               22487   1638   728.42   10.4 (4.3; 16.2)    18271   1252   685.24   15.8 (9.5; 21.6)

  12--23 months   13817                                 1309                        947.38                               13492   995    737.47   22.2 (15.5; 28.3)   14138   803    567.97   40.1 (34.5; 45.1)

  24--59 months   18423                                 1298                        704.55                               17990   1294   719.29   2.1 (-5.8; 9.3)     15717   880    559.90   20.5 (13.4; 27.1)

  \<5 years       55269                                 4480                        810.58                               53969   3927   727.64   10.2 (6.3; 14.0)    48126   2935   609.86   24.8 (21.3; 28.2)

  5--15 years     36846                                 971                         263.53                               35980   921    255.98   2.9 (-6.3; 11.2)    32926   748    227.18   13.8 (5.2; 21.6)

  0--15 years     92115                                 5451                        591.76                               89949   4848   538.97   8.9 (5.3; 12.4)     81052   3683   454.40   23.2 (19.9; 26.4)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Per 10.000 hospital discharges

PP rate was significantly reduced for all age groups during both the intervention year and the postVp ([Table 2](#pone.0199989.t002){ref-type="table"} and [Fig 2](#pone.0199989.g002){ref-type="fig"}).

![Discharge rate of pneumococcal pneumonia by age group during 2007--2014.](pone.0199989.g002){#pone.0199989.g002}

10.1371/journal.pone.0199989.t002

###### Pneumococcal pneumonia discharge rates by age.

PCV13 vaccination impact.

![](pone.0199989.t002){#pone.0199989.t002g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age Group       Pre-Vaccination Period: 2007--2011\   Intervention Period: 2012   Post-Vaccination Period: 2013--14\                                                                    
                  (Annual average)                                                  (Annual Average)                                                                                      
  --------------- ------------------------------------- --------------------------- ------------------------------------ ------- ----- ------- ------------------- ------- ------ ------- -------------------
  0--11 months    23029                                 69                          29.96                                22487   19    8.45    71.8 (53.1; 83.0)   18271   18.5   10.13   66.2 (43.6; 79.8)

  12--23 months   13817                                 59                          42.70                                13492   17    12.60   70.5 (40.4; 82.8)   14138   13.5   9.55    77.6 (59.6; 87.6)

  24--59 months   18423                                 87                          47.22                                17990   49    27.24   42.3 (18.2; 59.4)   15717   26.5   16.86   64.3 (44.9; 76.9)

  \<5 years       55269                                 215                         38.90                                53969   85    15.75   59.5 (48.0; 68.5)   48126   58.5   12.16   68.8 (58.3; 76.6)

  5--15 years     36846                                 87                          23.61                                35980   41    11.40   51.7 (30.0; 66.7)   32926   34     10.33   56.3 (35.0; 70.6)

  0--15 years     92115                                 302                         32.79                                89949   126   14.01   52.3 (47.4; 65.3)   81052   92.5   11.41   65.0 (55.8; 72.3)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Per 10.000 hospital discharges

Epidemiological-clinical patterns of PP cases after PCV13 vaccine introduction {#sec017}
------------------------------------------------------------------------------

Epidemiological-clinical data of 297 patients with PP were obtained; 59.3% males, mean age 54.8 months (standard deviation 45.1), median age 45.0 months (range 0--188); 53.2% had underlying illnesses, of which chronic respiratory infections were the most frequent in 27.9%; PCV13 coverage rate in children \<2 years of age with vaccination record was 42.9% in 2012 and 84.5% in the postVp.

Clinical characteristics of patients with PP, and penicillin susceptibility of pneumococcal isolates in the intervention year and in the postVp are described in [Table 3](#pone.0199989.t003){ref-type="table"}. There were no significant differences in the patient characteristics during the 3-year follow-up.

10.1371/journal.pone.0199989.t003

###### Pneumococcal pneumonia cases features after PCV13 vaccine introduction.

![](pone.0199989.t003){#pone.0199989.t003g}

  -----------------------------------------------------------------------------------------------------------------------------
  Features                                Total   Intervention Period\   Post-Vaccination Period\   p                   
                                                  2012                   2013--2014                                     
  --------------------------------------- ------- ---------------------- -------------------------- ------ ----- ------ -------
  Pneumococcal Pneumonia                  297                            106                               191          

  Penicillin resistant S.peumoniae        10      3.4                    6                          5.7    4     2.1    0.175

  Intermediate Resistance                 2       0.7                    2                          1.9    0     0      

  Age \<2 years                           93      31.3                   29                         27.4   64    33.5   0.335

  Underlying disease                      158     53.2                   59                         55.7   99    51.8   0.609

  Malnutrition                            23      7.7                    10                         9.4    13    6.8    0.558

  Recent acute respiratory disease        82      27.6                   24                         22.6   58    30.4   0.197

  Previous antibiotics (last 3 months)    55      18.5                   22                         20.8   33    17.3   0.560

  Previous hospitalizations (last year)   110     37.0                   40                         37.7   70    36.6   0.952

  Complications                           177     59.6                   63                         59.4   114   59.7   1.000

      Pleural effusion/empyema            152     51.2                   59                         55.7   93    4.7    0.303

      Necrotizing pneumonia               24      8.1                    12                         11.3   12    6.3    0.192

      Pneumothorax                        10      3.4                    2                          1.9    8     4.2    0.503

      Atelectasis                         9       3.0                    3                          2.8    6     3.1    1.000

      Others                              **9**   3.0                    3                          2.8    6     3.1    1.000

  Case-fatality rate                      10      3.4                    2                          1.9    8     4.2    0.503
  -----------------------------------------------------------------------------------------------------------------------------

Global case-fatality rate was 3.4% and was greater in children \<2 years of age (6.5%; 6/93) than in children 2 to 15 years (2.0%; 4/204), although the difference was not statistically significant (p = 0.076). No significant difference was found between case-fatality rate during the intervention period and that of the postVp (p = 0.503).

Microbiological diagnosis and serotype distribution {#sec018}
---------------------------------------------------

Microbiological diagnosis was performed in 318 samples from 297 patients: blood (237; 74.5%) and pleural fluid (81; 25.5%); in 21 patients, Sp was isolated in both blood and pleural fluid. Penicillin resistance (PR) was 3.4%, intermediate susceptibility was 0.7%.

Sp isolates were serotyped in 43.1% of patients (128/297) [Fig 3](#pone.0199989.g003){ref-type="fig"}.

![Pneumococcal pneumonia cases after PCV13 vaccine introduction: Distribution of *S*. *pneumoniae* serotypes.\
\*Partially typeable pools: C \[24, 31 ó 40\], G \[29,34,35,42 or 47\], H \[13 ó 28\], I \[38, 25F or 25A\].](pone.0199989.g003){#pone.0199989.g003}

Serotypes included in PCV13 decreased from 83.0% (39/47) in 2012 to 64.2% (52/81) in the postVp, p = 0.039.

The most frequently identified serotype was 1 which did not show significant changes over the 3-year study period. Serotype 14 was the second most common serotype, decreasing significantly from 9 isolations in 2012, to 2 in 2013 and 1 in 2014 (9/47 to 3/81; p = 0.008).

Discussion {#sec019}
==========

Estimating the burden of CP in the pediatric population under WHO guidelines and specific rates of microbiologically confirmed PP are appropriate criteria to evaluate the impact of PCVs programs. In this study, as in other national and Latin American studies, a decrease in the burden of pneumonia in children was observed after the introduction of PCV13 in the national calendar \[[@pone.0199989.ref019]--[@pone.0199989.ref023]\].

An overall reduction in CP rates in children under 5 years was observed, more remarkably in the postVp; a greater impact was observed in young children 12 to 23 months of age during both periods in spite of a fall in booster dose coverage in the second year of life.

CP also decreased significantly in Infants \< one year of age in both periods but less than in the group aged 12 to 23 months. This could be related to a greater incidence of respiratory viral infections in infants under 12 months and a direct relationship between bacterial etiology and age \[[@pone.0199989.ref024]\].

On the other hand, several studies have described that viral infections can cause localized alveolar infiltrate (lung consolidation) \[[@pone.0199989.ref025], [@pone.0199989.ref026]\], and other authors have reported increased incidence of pneumonia in association with viral diseases, such as influenza, parainfluenza, RSV, adenovirus, or metapneumovirus \[[@pone.0199989.ref027]--[@pone.0199989.ref032]\].

In a case control study, upper respiratory infections caused by viruses like influenza and parainfluenza correlated with acquisition of new serotypes of Sp in children \[[@pone.0199989.ref033]\].

In our study almost 30% of patients with PP had a history of a recent acute respiratory infection. Regarding the impact of PCV13 on PP rates, a significant reduction was observed among children in both vaccinated and nonvaccinated age-groups. Several studies describe this decline coinciding with emergence of less frequent non-vaccine serotypes, reinforcing the need for continued PP and invasive pneumococcal disease surveillance \[[@pone.0199989.ref034], [@pone.0199989.ref035]\].

As Weinberger et al. \[[@pone.0199989.ref036]\] suggest, the duration of the post-vaccination follow-up period can influence the magnitude of changes in disease incidence. There appears to be a lag between vaccine introduction and an increase in invasive pneumococcal disease (IPD) caused by non-vaccine serotypes. This could be attributed to the amount of time required to reach full vaccine coverage and for vaccine serotypes to be eliminated, especially through herd effects in the general population.

One weakness of our study is the lack of information of pneumococcal serotypes in the preVp as well as scarce epidemiological-clinical data in this period. Also, in only about half of the patients could a serotype be identified, mainly due to logistic difficulties in sending samples to the reference laboratory, or in other cases because PCR technique was used. However, a significant decrease in vaccine serotypes could be shown, as well as a relative increase in non-vaccine serotypes in the postVp.

It is important to highlight that PCV13 covers 85% of serotypes involved in all IPD and 88.4% of those causing pneumonia according to data 2011 from SIREVA II (Network Surveillance System for the Bacterial Agents Responsible for Pneumonia and Meningitis) \[[@pone.0199989.ref037]\].

Serotype 1, which is included in PCV13, was the most commonly isolated serotype during the 3-year study period, a phenomenon also described in other countries with other vaccine serotypes. During 2011, in a surveillance study for IPD at eight children's hospitals in the United States, serotypes 19A and 7F remained the most common ones isolated from children hospitalized with pneumonia \[[@pone.0199989.ref038]\]. In another study, serotype 3 was isolated from pleural fluid specimens in 15 of 20 children with pneumococcal empyema, one-third of whom had received PCV13 \[[@pone.0199989.ref039]\]. In addition, serotype 1 is of special interest since it has exhibited a secular trend with long-term fluctuations, as has been reported in other countries \[[@pone.0199989.ref040]\]. Serotypes 19A, 7F and 3 remained low in prevalence, as historically seen in Argentina \[[@pone.0199989.ref041]\].

Regarding serotype 14, it is important to highlight low recovery of this serotype in the postVp, taking into account that it had been the predominant cause of IPD, mainly pneumonia, in the pre-vaccination era in our country \[[@pone.0199989.ref041], [@pone.0199989.ref042]\].

Sp resistance to multiple antibiotics is an important clinical problem. However, in our study resistance to penicillin was low. This could be related with changes in definitions in susceptibility cut-offs \[[@pone.0199989.ref018]\] as well as to the introduction of PCV13 to the program.

Sixty percent of patients with PP showed complications, a percentage slightly higher than levels reported in the literature, which range from 40 to 50% \[[@pone.0199989.ref043], [@pone.0199989.ref044]\], and included the classically reported complications \[[@pone.0199989.ref045]--[@pone.0199989.ref047]\], mainly pleural effusion/empyema, followed by necrotizing pneumonia, pneumothorax and atelectasis.

In the United States, PP complicated by pleural effusion/empyema increased in frequency in the period prior to the universal introduction of pneumococcal conjugate vaccine in 2000, and continued increasing after vaccine introduction \[[@pone.0199989.ref048], [@pone.0199989.ref049]\].

In our study, in the postVp, the decrease of PP cases was not associated with an increase in pleural effusion or other complications. Most of the children with PP, even those with complicated PP, recovered without sequelae.

PP case fatality rate (3.4%) was similar to that described in the literature, and was higher in children \<2 years \[[@pone.0199989.ref050]\].

Conclusions {#sec020}
===========

After the introduction of PCV13 into the National Immunization Program, our study has shown a significant decrease in the burden of pneumonia in children, mainly in the group 12 to 23 months of age, a significant decrease in vaccine serotypes as well as a rise in non-vaccine serotypes, and low pneumococcal resistance to penicillin.

The decrease in PP cases was not associated with an increase in pleural effusion or other complications.

Supporting information {#sec021}
======================

###### PCV13 vaccination impact on pneumonia discharge rates.

Pneumococcal Pneumonia cases features.

(DOCX)

###### 

Click here for additional data file.

The authors would like to thank all working group members for their generous contributions to this effort: Norma Fernández, Macarena Uranga, Nanci Miguez, Carolina Aguirre, Ivana Morales, Laura Miño, Pablo Scoleri, Maria Rosa Baroni, Maria Rosa Miranda, Patricia Carrizo Herrera, Mabel Regueira, Omar Veliz and Cecilia Sorhouet.

Lead author for Working Group: Julia Bakir e-mail: <jalude60@yahoo.com.ar>

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: ¶ Membership of the Working Group can be found in the Acknowledgments.
